Comparing the effect of agomelatine and sertraline in treating patients with major depression disorder

Document Type : Original Article

Authors

1 Psychiatry Department, Clinical Research Development Unit, Matini/Kargarnejad Hospitals, Kashan University of Medical Sciences, Kashan, Iran

2 Psychiatry Department, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran

3 Department of Epidemiology and Biostatistics, School of Health,Kashan University of Medical Sciences, Kashan, Iran

Abstract

Objectives: This study compared the effect of agomelatine and sertraline in treating patients with major depressive disorder (MDD).
Methods: This single‑blinded clinical trial was conducted on 52 patients aged 18–65 years with major depression (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) in Kashan in 2020. The Hamilton Rating Scale was randomly assigned agomelatine (25–50 mg/day) or sertraline (50–200 mg/day) for 8 weeks. The main efficacy outcome was considered a mean change of HAM‑D score from the baseline to the end of therapy.
Results: The drugs under study effectively reduced depressive symptoms at all time points. As a frequent analysis showed, changes in Hamilton score were found to be significant in both the groups over time (F = 45.48, P < 0.001). Comparing the two groups showed a significant difference, such that score reduction was higher in the sertraline group (F = 4.45, P = 0.04). However, due to the differences between the two groups in terms of age and sex, the data were re‑analyzed using a linear regression analysis with a random effect model approach. After removing the effect of age and sex as two confounding variables, we observed no significant differences between the two groups.
Conclusion: Agomelatine is more effective than sertraline in treating MDD.

Highlights

Marzieh Barati Karizno [Pubmed] [Google Scholar]

Keywords

References

  1. Golan DE, Tashjian AH, Armstrong EJ. Principles of pharmacology: the pathophysiologic basis of drug therapy: Lippincott Williams & Wilkins; 2011.
  2. Milenkovic VM, Stanton EH, Nothdurfter C, Rupprecht R, Wetzel CH. The role of chemokines in the pathophysiology of major depressive disorder. International journal of molecular sciences. 2019;20(9):2283. doi:10.3390/ijms20092283 PMid:31075818 PMCid:PMC6539240
  3. Zhao W, Zhu D-m, Zhang Y, Zhang C, Wang Y, Yang Y, et al. Pineal gland abnormality in major depressive disorder. Psychiatry Research: Neuroimaging. 2019;289:13-7. doi:10.1016/j.pscychresns.2019.05.004 PMid:31121531
  4. Huddart R, Hicks JK, Ramsey LB, Strawn JR, Smith DM, Babilonia MB, et al. PharmGKB summary: sertraline pathway, pharmacokinetics. Pharmacogenetics and genomics. 2020;30(2):26. doi:10.1097/FPC.0000000000000392 PMid:31851125 PMCid:PMC7008964
  5. Fasipe OJ. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO reports. 2019;6:95-110. doi:10.1016/j.ibror.2019.01.001 PMid:31211282 PMCid:PMC6562183
  6. Emet M, Ozcan H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A. A review of melatonin, its receptors and drugs. The Eurasian journal of medicine. 2016;48(2):135. doi:10.5152/eurasianjmed.2015.0267
    PMid:27551178 PMCid:PMC4970552
  7. Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sci. 2018;210:177-84. doi:10.1016/j.lfs.2018.09.003 PMid:30193943
  8. Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Therapeutic advances in psychopharmacology. 2018;8(1):13-23. doi:10.1177/2045125317720642 PMid:29344340 PMCid:PMC5761906
  9. Gharaei B,Mehryar AH,Mehrabi F.The Attribution style in patients with Anxiety and Depression. Andeeshe va Raftar.2000:5(4)37-42
  10. Trajković G, Starčević V, Latas M, Leštarević M, Ille T, Bukumirić Z, et al. Reliability of the Hamilton Rating Scale for Depression: a meta-analysis over a period of 49 years. Psychiatry research. 2011; 189(1):1-9. doi:10.1016/j.psychres.2010.12.007
    PMid:21276619
  11. Lam RW. The importance of early symptom relief in antidepressant treatment: focus on agomelatine. Journal of Psychopharmacology. 2010;24(2_suppl):27-30. doi:10.1177/1359786810372979 PMid:20663806
  12. Kennedy SH. Agomelatine: efficacy at each phase of antidepressant treatment Cns Drugs. 2009;23(2):41-7.
    doi:10.2165/11318660-000000000-00000 PMid:19708725
  13. Akpınar E, Cerit C, Talas A, Tural Ü. Agomelatine versus sertraline: an observational, open-labeled and 12 weeks follow-up study on efficacy and tolerability. Clinical Psychopharmacology and Neuroscience. 2016;14(4):351. doi:10.9758/cpn.2016.14.4.351
    PMid:27776387 PMCid:PMC5083946
  14. Talas A, Cerit C, Akpınar Aslan E. Comparison of the effects of sertraline and agomelatine on sleep quality, sexual functioning and metabolic parameters in patients with major depressive disorder. Psychiatry and Clinical Psychopharmacology. 2019;29(3):257-63. doi:10.1080/24750573.2018.1490096
  15. Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. Journal of molecular psychiatry. 2015;3(1):1-12. doi:10.1186/s40303-015-0011-7 PMid:25932327 PMCid:PMC4407422
  16. Raymond W L. The importance of early symptom relief in antidepressant treatment: focus on agomelatine. J Psychopharmacol. 2010;24(2 Suppl):27-30. doi:10.1177/1359786810372979 PMid:20663806
  17. Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug safety. 2011;34(9):709-31. doi:10.2165/11593960-000000000-00000 PMid:21830835
  18. Firake BM, Siddaiah M, Pathak PV. Review on Agomelatine: A Novel Melatonergic Antidepressant. Int J Adv Res i Pharm Educ. 2019;1(1):1-8. Corpus ID: 226769846.
  19. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. International clinical psychopharmacology. 2002;17(5):239-47. doi:10.1097/00004850-200209000-00004 PMid:12177586
  20. Plesničar BK. Efficacy and tolerability of agomelatine in the treatment of depression. Patient preference and adherence. 2014; 8:603. doi:10.2147/PPA.S42789 PMid:24833894 PMCid:PMC4014359
  21. Kennedy SH, Heun R, Avedisova A, Ahokas A, Olivier V, Picarel-Blanchot F, et al. Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder. J affective disorders. 2018;238:122-8. doi:10.1016/j.jad.2018.05.060
    PMid:29879606
  22. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder. CNS drugs. 2010;24(6):479-99. doi:10.2165/11534420-000000000-00000 PMid:20192279
  23. Potměšil P. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice? Ther advances psychopharmacology. 2019;9. doi:10.1177/2045125319855206 PMid:31312426 PMCid:PMC6614940
  24. Olié JP, Kasper S. Efficacy of agomelatine, a MT 1/MT 2 receptor agonist with 5-HT 2C antagonistic properties, in major depressive disorder. The The International Journal of Neuropsychopharmacology. 2007;10(5):661-73. doi:10.1017/S1461145707007766 PMid:17477888
  25. Hsing S-C, Jin Y-T, Tzeng N-S, Chung C-H, Chen T-Y, Chang H-A, et al. Is Agomelatine Associated with Less Sedative-Hypnotic Usage in Patients with Major Depressive Disorder? A Nationwide, Population-Based Study. Neuropsychiatric Disease and Treatment. 2020;16:1727. doi:10.2147/NDT.S257723
    PMid:32801707 PMCid:PMC7384877
  26. Yardimci A, Kelestimur H. Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model. Frontiers in Psychiatry. 2021 doi:10.3389/fpsyt.2021.654616 PMid:34267684 PMCid:PMC8275877
  27. Guardiola-Lemaitre C, Delagrange P, Millan MJ, Munoz C, Mocaër E. Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171:3604-19. doi:10.1111/bph.12720 PMid:24724693 PMCid:PMC4128060
International Archives of Health Sciences
Volume 10, Issue 3
September 2023
Pages 122-129

Files

History

  • Receive Date: 22 April 2023
  • Revise Date: 12 July 2023
  • Accept Date: 15 August 2023

Share

How to cite

Statistics